<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="case-report">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">BMC Res Notes</journal-id>
      <journal-id journal-id-type="iso-abbrev">BMC Res Notes</journal-id>
      <journal-title-group>
        <journal-title>BMC Research Notes</journal-title>
      </journal-title-group>
      <issn pub-type="epub">1756-0500</issn>
      <publisher>
        <publisher-name>BioMed Central</publisher-name>
        <publisher-loc>London</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">26055103</article-id>
      <article-id pub-id-type="pmc">4467666</article-id>
      <article-id pub-id-type="publisher-id">1215</article-id>
      <article-id pub-id-type="doi">10.1186/s13104-015-1215-8</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Case Report</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Summertime dosage-dependent hypersensitivity to an angiotensin II receptor blocker</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author" corresp="yes">
          <name>
            <surname>Forsdyke</surname>
            <given-names>Donald R</given-names>
          </name>
          <address>
            <email>forsdyke@queensu.ca</email>
          </address>
          <xref ref-type="aff" rid="Aff1"/>
        </contrib>
        <aff id="Aff1">Department of Biomedical and Molecular Sciences, Queen&#x2019;s University, Kingston, ON K7L3N6 Canada </aff>
      </contrib-group>
      <pub-date pub-type="epub">
        <day>9</day>
        <month>6</month>
        <year>2015</year>
      </pub-date>
      <pub-date pub-type="pmc-release">
        <day>9</day>
        <month>6</month>
        <year>2015</year>
      </pub-date>
      <pub-date pub-type="collection">
        <year>2015</year>
      </pub-date>
      <volume>8</volume>
      <elocation-id>227</elocation-id>
      <history>
        <date date-type="received">
          <day>8</day>
          <month>4</month>
          <year>2014</year>
        </date>
        <date date-type="accepted">
          <day>29</day>
          <month>5</month>
          <year>2015</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>&#xA9; Forsdyke 2015</copyright-statement>
        <license license-type="OpenAccess">
          <license-p>
<bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p>
        </license>
      </permissions>
      <abstract id="Abs1">
        <sec>
          <title>Background</title>
          <p>Summertime dips in blood pressure (BP), both in normotensive and hypertensive subjects, are well known. However, the dips are small and are not related to particular forms or doses of antihypertensive medication. Nevertheless it is the practice in some quarters to decrease antihypertensive medication in summer, and/or to increase in winter. Large scale studies being inconclusive, there are calls for long-term examination of the relationship between environmental temperature and blood pressure in single individuals under medication.</p>
        </sec>
        <sec>
          <title>Case presentation</title>
          <p>While analyzing data from a subject whose BP had been controlled for a decade with the angiotensin-II receptor blocker losartan, an extreme, dosage-dependent, summertime dip came to light. Downward dosage adjustment appeared essential and may have prevented hypotension-related pathology.</p>
        </sec>
        <sec>
          <title>Conclusion</title>
          <p>The benefits of aggressive medication (the &#x201C;J curve&#x201D; phenomenon) being debated, the possibility of seasonal hypersensitivity, perhaps explicable in terms of differential signaling by countervailing receptors, should be taken into account when considering dosage adjustments in hypertensive subjects.</p>
        </sec>
      </abstract>
      <kwd-group xml:lang="en">
        <title>Keywords</title>
        <kwd>Environmental temperature</kwd>
        <kwd>Angiotensin II receptor</kwd>
        <kwd>Losartan</kwd>
        <kwd>Hypotension</kwd>
        <kwd>Acute kidney injury</kwd>
        <kwd>J-curve</kwd>
      </kwd-group>
      <custom-meta-group>
        <custom-meta>
          <meta-name>issue-copyright-statement</meta-name>
          <meta-value>&#xA9; The Author(s) 2015</meta-value>
        </custom-meta>
      </custom-meta-group>
    </article-meta>
  </front>
  <body>
    <sec id="Sec1">
      <title>Background</title>
      <sec id="Sec2">
        <title>Conflicting opinions on seasonal dosage adjustment</title>
        <p>Small summertime declines in blood pressure (e.g. 5&#x2013;10&#xA0;mm&#xA0;Hg) have long been known, both in normotensive and hypertensive subjects. Indeed, adverse cardiovascular events being more frequent in winter, it is the practice in some quarters to decrease antihypertensive medication in summer, and/or increase in winter [<xref ref-type="bibr" rid="CR1">1</xref>]. But this is controversial. Ambulatory blood pressure (ABP) recordings often reveal a small dip in BP values when subjects are resting at night [<xref ref-type="bibr" rid="CR2">2</xref>]. In Italy, Modesti et al. reported in 2006 [<xref ref-type="bibr" rid="CR3">3</xref>] that in summer this night-time dipping was less evident, and systolic values (SBPs) were slightly <italic>increased</italic>; it was only with day-time BP measurements that a summer decrease was evident. They cautioned against reducing dosage of antihypertensive medication in hot weather. On the other hand, based on clinic BP measurements of 500,000 subjects drawn from ten climatically diverse regions of China, in 2012 Lewington et al. [<xref ref-type="bibr" rid="CR4">4</xref>] affirmed that &#x201C;higher doses or additional drug(s) may be required in winter to achieve the same blood pressure control as at other times of the year&#x201D;. In other words, they advised lowering dosage in summertime. Indeed, in 2013 Modesti came to agree that &#x201C;it is possible that heat-exposed subjects need lower dosages&#x2026; because of lower BP in warm conditions&#x201D; [<xref ref-type="bibr" rid="CR5">5</xref>].</p>
        <p>However, seasonal influences on responses to specific antihypertensive medications are not well documented. Apart from logistic considerations (e.g. patient confidentiality), this may be due the relative newness of some medications, so that long-term studies are not yet available. In Japan, Hozawa et al. [<xref ref-type="bibr" rid="CR6">6</xref>] relied on the home BP measurements of volunteers, but had no information on medications. In Scotland, Aubini&#xE8;re-Robb et al. [<xref ref-type="bibr" rid="CR7">7</xref>] relied on clinic measurements of treated hypertensive subjects, but had &#x201C;incomplete prescribing data&#x201D;. Furthermore, their location implied more concern for potential adverse effects of increases in BP in cold weather, than of decreases in BP in hot weather. The subtropical island of Taiwan has temperatures closer to those in summer-time Ontario, but the winter-summer variation is much less. For Taiwan, Tu et al. [<xref ref-type="bibr" rid="CR8">8</xref>] reported no influence of season on the response to antihypertensive medication, but type and dosage were unspecified.</p>
        <p>The most definitive study to date is the above noted work of Lewington et al. [<xref ref-type="bibr" rid="CR4">4</xref>]. The <italic>percentage</italic> differences between summer and winter did not differ between those on antihypertensive medication (type unspecified), and those who were not. However, <italic>absolute</italic> differences were greater in hypertensive subjects (differences averaging 11.0 versus 9.6&#xA0;mm Hg). Floras has recently cautioned that when marginal hypertension is diagnosed in summer-time, initiating therapeutic dosages may be suboptimum, but the possibility of extreme seasonal variation in sensitivity to medication was not entertained [<xref ref-type="bibr" rid="CR9">9</xref>].</p>
      </sec>
      <sec id="Sec3">
        <title>Calls for long-term single patient studies</title>
        <p>Despite many studies, seasonal variations in BP are not clearly related to particular forms or dosages of medication in individual subjects. It is recognized that &#x201C;patients are exposed to antihypertensive treatment for decades; yet, long-term safety of these drugs is not well-reported. Most prospective randomised trials end after a few years without long-term follow up&#x201D; [<xref ref-type="bibr" rid="CR10">10</xref>]. Indeed, in 2013 Modesti et al. [<xref ref-type="bibr" rid="CR11">11</xref>] declared that some of the limitations of their approach &#x201C;would be addressed in future studies based on repeated measurements according to a longitudinal design and focusing on the assessment of temperature and BP changes within a single individual&#x201D;. This need for long-term single-individual studies was echoed in 2012 by Cuspidi et al. [<xref ref-type="bibr" rid="CR12">12</xref>], and in 2013 by Tomlinson et al. [<xref ref-type="bibr" rid="CR13">13</xref>], who called for &#x201C;carefully designed studies using individual level patient data to examine this issue in more depth&#x201D;. To some extent, the present study meets this requirement, but regrettably with the absence of night readings. In 2011 Handler [<xref ref-type="bibr" rid="CR14">14</xref>] reported a case where the subject, based on home BP readings and postural hypotension, had opted to stop medication in summer, but there were few details. In 2013 Chen et al. [<xref ref-type="bibr" rid="CR15">15</xref>] reported a 3&#xA0;year follow-up of hypertensives treated with the angiotensin converting enzyme (ACE) inhibitor (benazepril); average seasonal fluctuations were of the same order as reported by Lewington et al. [<xref ref-type="bibr" rid="CR4">4</xref>]. It was concluded that &#x201C;patients should monitor and treat blood pressure more carefully in cold days&#x201D;.</p>
      </sec>
      <sec id="Sec4">
        <title>J-curve phenomenon</title>
        <p>Seasonal BP variations are not seen as related to the so-called &#x201C;J curve&#x201D; phenomenon [<xref ref-type="bibr" rid="CR16">16</xref>]. While the benefits of decreasing blood pressure are clear, there comes a point below which there are negative consequences, marked by a J-like inflection on plots of adverse cardiovascular events against BP. Such consequences include acute kidney injury, now becoming more evident among those on medication [<xref ref-type="bibr" rid="CR13">13</xref>]. Indeed, it is held that its &#x201C;important implications for clinical practice should make investigation on the J-curve phenomenon a priority for cardiovascular medicine&#x201D; [<xref ref-type="bibr" rid="CR16">16</xref>].</p>
        <p>While analyzing data from a subject whose BP had been controlled for a decade with the angiotensin-II receptor blocker (ARB) losartan, an extreme, potentially dangerous, summer-time influence came to light [<xref ref-type="bibr" rid="CR17">17</xref>]. ARBs being treatment of choice for millions of subjects, it is unlikely this is an isolated case.</p>
      </sec>
    </sec>
    <sec id="Sec5">
      <title>Case presentation</title>
      <sec id="Sec6" sec-type="materials|methods">
        <title>Materials and methods</title>
        <p>In August 1999, mild hypertension (circa 150/90&#xA0;mm Hg) was found during routine examination of a 60&#xA0;year old biomedical researcher. In the 1960s he had been briefly involved in hypertension research<sup>a</sup>. When studying the activation of cultured human lymphocytes in the 1980s he discovered a gene (<italic>RGS</italic>-<italic>2</italic>) [<xref ref-type="bibr" rid="CR18">18</xref>] that was later found to regulate BP [<xref ref-type="bibr" rid="CR19">19</xref>, <xref ref-type="bibr" rid="CR20">20</xref>]. With appreciation of possible immunological aspects of hypertension [<xref ref-type="bibr" rid="CR21">21</xref>], he followed the course of his new condition with deep professional interest. This led to his carrying out all readings for, and authoring, the present report. Beginning in January 2000, resting BP readings were taken at least once daily (usually both in early morning and late evening) by the subject at his home. The continuing accuracy of his Omron digital BP monitor (model HEM-712C) was ascertained by comparing with readings from his mercury sphygmomanometer, with those obtained in his physician&#x2019;s office<sup>b</sup> and, in 2015, by comparing with a new Omron monitor (HEM-7121C).</p>
        <p>Since Ontario Climate Centre records of daily temperatures for the subject&#x2019;s lakeside city (Kingston, Ontario) did not become available until 2008, values for a location 24&#xA0;km north (Hartington) were employed. The latter tends to be 2&#x2013;3&#xB0; cooler/hotter in winter/summer than Kingston. In the period of this study, indoor temperatures were regulated at around 22&#xB0;C during cold weather. In summer months fans were employed and only short periods were spent in air-conditioned environments.</p>
        <p>Throughout the study period standard blood and urine tests remained within normal ranges, except that on occasions creatinine levels approached high normal. The subject&#x2019;s resting pulse had registered around 50/min for many years. His lifestyle was that of an academic workaholic&#x2014;several hours a day at a computer interrupted by frequent brisk walks, and twice weekly runs (2&#xA0;km). Height and weight had remained relatively constant throughout adult life (currently 1.76&#xA0;m and 72&#xA0;kg; BMI&#xA0;=&#xA0;23.2). The hypertension was assumed to be primary (&#x2018;essential&#x2019;), and was not further investigated. However, at an early stage antihypertensive medication was associated with postural hypotension and an instance of acute renal colic. These encouraged close home BP monitoring with dosage adjustment by the subject targeting 130/80&#xA0;mm&#xA0;Hg. While the present report is primarily concerned with a 12&#xA0;year period when losartan was the sole medication (2003&#x2013;2014), the stage will be set with a brief account of an initial 3&#xA0;year exploratory period with various other medications.</p>
      </sec>
      <sec id="Sec7">
        <title>The period 2000&#x2013;2002</title>
        <p>In the year 2000, two one-month trials (Feb., Apr.) of daily losartan (25&#xA0;mg) with chlorothiazide (12.5&#xA0;mg) resulted in progressive falls in day-time BP, with some systolic values (SBP) around 100&#xA0;mm Hg (Figure&#xA0;<xref rid="Fig1" ref-type="fig">1</xref>). Consistent with this, the subject experienced some dizziness on standing up abruptly. On cessation of these medications, BP values progressively returned to previous levels.<fig id="Fig1"><label>Figure&#xA0;1</label><caption><p>Daily variation in SBP (<italic>black circles</italic>) and DBP (<italic>grey circles</italic>) over a 3&#xA0;year period, as related to (1) maximum daily environmental temperatures (<italic>small black squares</italic>) and (2) periodic treatments at constant dosage with losartan (<italic>red triangles</italic>), chlorothiazide (<italic>green triangles</italic>) or ramipril (<italic>blue triangles</italic>). At <italic>bottom right</italic>, the two rows of <italic>red triangles</italic> mark the initiation of a 12&#xA0;year period (2003&#x2013;2014) where the day-to-day dosage of losartan was varied. Renal colic in the year 2000 is marked by a large <italic>red triangle</italic>. At that time home BP measurements were usually taken 2&#x2013;3 times a day&#x2014;in the early morning, in the early afternoon, and in the evening. All measurements are directly plotted. <italic>Gaps</italic> indicate periods of travel when readings were discontinued. Since records of temperature values for the subject&#x2019;s lakeside city (Kingston, Ontario) did not become available until 2008, values for a location 24&#xA0;km north (Hartington) were employed.</p></caption><graphic xlink:href="13104_2015_1215_Fig1_HTML" id="MO1"/></fig></p>
        <p>In June, chlorothiazide alone (12.5&#xA0;mg) had little effect. However, losartan alone (25&#xA0;mg), taken at the height of summer (August, with environmental temperatures approaching 30&#xB0;C), produced a progressive and more profound fall in pressure, with SBP values again below 100&#xA0;mm Hg, and diastolic (DPB) values approaching 60&#xA0;mm&#xA0;Hg. Shortly after cessation of therapy there was acute renal colic and blood pressure rose abruptly (Figure&#xA0;<xref rid="Fig1" ref-type="fig">1</xref>). A ureteral stone observed on X-rays was presumed to have passed in the urine.</p>
        <p>In view of the timing, and the subject not having previously experienced renal colic, it was considered likely that stone formation had been facilitated by hypotension. Indeed, there is now increasing awareness that acute kidney injury (AKI) can follow ARB medication in a range of settings, particularly during acute hypovolemic illness [<xref ref-type="bibr" rid="CR13">13</xref>]. Medications were avoided for the next 2&#xA0;years and pressure values remained relatively constant in the 150/90 range. In the summer of 2001 there was the expected small BP dip, which correlated inversely with environmental temperature (Figure&#xA0;<xref rid="Fig2" ref-type="fig">2</xref>).<fig id="Fig2"><label>Figure&#xA0;2</label><caption><p>Seasonal variation in SBP and DBP in absence of hypertensive medication. Daily values for each month in the year 2001 are averaged and plotted with standard errors. Corresponding monthly average temperature values are shown without symbols (maximum, <italic>continuous red line</italic>; average, <italic>dashed black line</italic>; minimum, <italic>dotted blue line</italic>).</p></caption><graphic xlink:href="13104_2015_1215_Fig2_HTML" id="MO2"/></fig></p>
        <p>In the summer of 2002 mild hypertension was confirmed by one session of 24&#xA0;h ambulatory BP (ABP) monitoring and, for a 6&#xA0;week period (beginning in the last week of July), daily combination therapy with losartan (25&#xA0;mg) and chlorothiazide (12.5&#xA0;mg) was resumed (Figure&#xA0;<xref rid="Fig1" ref-type="fig">1</xref>). Again, there were extreme declines in pressure values and some minor dizzy episodes. BP was controlled more satisfactorily with the ACE inhibitor, ramipril (2.5&#xA0;mg/day; late September to early December). However the subject experienced a persistent dry cough, so ramipril was discontinued. Although there had been some dry coughing with losartan, therapy with losartan alone was resumed at the end of December 2002 (rows of red triangles at extreme right in Figure&#xA0;<xref rid="Fig1" ref-type="fig">1</xref>). Dosage was adjusted daily by the subject according to his BP readings. This proved satisfactory for the next 12&#xA0;years, despite some dry coughing.</p>
      </sec>
      <sec id="Sec8">
        <title>The period 2003&#x2013;2014</title>
        <p>With various combinations of half (12.5&#xA0;mg) and whole (25&#xA0;mg) tablets, daily losartan dosage was varied over the range, 0, 12.5, 25, 37.7 and 50&#xA0;mg, taken either in the early morning or, from December 2010 onwards, split between mornings and evenings (under guidance of BP readings taken at the same times). Further fine adjustment was attempted by trying to maintain regular dosage patterns&#x2014;e.g. 12.5, 25, 12.5, 25&#xA0;mg, etc. Apart from weekly sildenafil citrate (50&#xA0;mg), which tended to lower BP, losartan was the sole medication.</p>
        <p>For the first 4&#xA0;years (2003&#x2013;2006) the required average losartan dose was 16&#xA0;mg/day, rising to 18&#xA0;mg/day for the next 3&#xA0;years (2007&#x2013;2009). Thereafter, the average requirement rose from 19&#xA0;mg/day (2010) to 44&#xA0;mg/day (2013) and 33&#xA0;mg/day (2014). An example of the ability to fine-tune day-time BP readings over the 2003-2009 period is shown for the year 2007 (Figure&#xA0;<xref rid="Fig3" ref-type="fig">3</xref>). With relatively constant losartan dosages (average 18&#xA0;mg/day) blood pressure readings were maintained at acceptable values (130/80&#xA0;mm Hg). There was generally no need for special dosage adjustments in the hot summer season.<fig id="Fig3"><label>Figure&#xA0;3</label><caption><p>Daily variation in SBP and DBP in 2007, as related to (1) maximum daily environmental temperatures and (2) varying losartan dosage. Home BP measurements were usually twice daily&#x2014;in the early morning and late evening&#x2014;and these values were averaged for plotting. Least-squares regression (sixth order) polynomial fits to the points are shown as <italic>continuous lines</italic> (the fit is third order for the <italic>black temperature line</italic>). For other details see Figure&#xA0;<xref rid="Fig1" ref-type="fig">1</xref>.</p></caption><graphic xlink:href="13104_2015_1215_Fig3_HTML" id="MO3"/></fig></p>
        <p>These same BP values were sustained in the 2010&#x2013;2014 period. However, when, for some unknown reason, the total losartan requirement <italic>increased</italic>, an extreme <italic>downward</italic> dosage adjustment became necessary in the summer season. This is shown for the year 2012 in Figure&#xA0;<xref rid="Fig4" ref-type="fig">4</xref>.<fig id="Fig4"><label>Figure&#xA0;4</label><caption><p>Daily variation in SBP and DBP in 2012, as related to (1) maximum daily environmental temperatures and (2) varying losartan dosage. For details see Figures&#xA0;<xref rid="Fig1" ref-type="fig">1</xref>, <xref rid="Fig3" ref-type="fig">3</xref>.</p></caption><graphic xlink:href="13104_2015_1215_Fig4_HTML" id="MO4"/></fig></p>
        <p>The detailed BP plot for 2011, when increased losartan dosage first became necessary, is of special interest (Figure&#xA0;<xref rid="Fig5" ref-type="fig">5</xref>). BP levels were maintained relatively constant by <italic>decreasing</italic> losartan dosage in the summer months and <italic>increasing</italic> dosage in the following winter. The sub-zero maximum daily temperatures early in the year were associated with 25&#xA0;mg/day dosages. The increase in losartan requirement to 50&#xA0;mg/day began in the late fall when maximum temperatures were still above zero, so seeming to reflect an influence internal to the subject, as well as from the environment.<fig id="Fig5"><label>Figure&#xA0;5</label><caption><p>Daily variation in SBP and DBP in 2011, as related to (1) maximum daily environmental temperatures and (2) varying losartan dosage. For details see Figures&#xA0;<xref rid="Fig1" ref-type="fig">1</xref>, <xref rid="Fig3" ref-type="fig">3</xref>.</p></caption><graphic xlink:href="13104_2015_1215_Fig5_HTML" id="MO5"/></fig></p>
        <p>Monthly losartan requirements for the entire 12&#xA0;year period are shown in Figure&#xA0;<xref rid="Fig6" ref-type="fig">6</xref>. At the doses employed between 2003 and 2009 (average 16&#x2013;18&#xA0;mg/day), usually no seasonal adjustment was needed. In 2006 (a particularly hot year), only minor adjustment was needed. The plot for 2011 was distinctive. At first the requirement was high, but decreased to previous values during spring and summer. However, later in the year as environmental temperature declined, there was a sharp increase in losartan requirement. Subsequently (2012&#x2013;2014), a summer requirement for extreme downward dosage adjustment emerged.<fig id="Fig6"><label>Figure&#xA0;6</label><caption><p>Monthly losartan requirements for a 12&#xA0;year period (2003&#x2013;2014). 2003, <italic>black triangles</italic>; 2004, <italic>dark yellow triangles</italic>; 2005, <italic>green circles</italic>; 2006, <italic>black squares</italic>; 2007, <italic>blue diamonds</italic>; 2008, <italic>orange squares</italic>; 2009, <italic>grey triangles</italic>; 2010, <italic>red diamonds</italic>; 2011, <italic>cyan circles</italic>; 2012, <italic>black circles</italic>; 2013, <italic>green diamonds</italic>; 2014, <italic>dark red circles</italic>. Data for 2012&#x2013;2014 include standard errors.</p></caption><graphic xlink:href="13104_2015_1215_Fig6_HTML" id="MO6"/></fig></p>
      </sec>
      <sec id="Sec9">
        <title>Relationship between temperature and BP</title>
        <p>Plots of BP and losartan dosage against temperature showed minimal influence of temperature during the 2003&#x2013;2009 period. Figure&#xA0;<xref rid="Fig7" ref-type="fig">7</xref> shows data for 2007 (from Figure&#xA0;<xref rid="Fig3" ref-type="fig">3</xref>). The regression line for losartan dosage (red) was essentially horizontal. However, plots for the year 2011 (Figure&#xA0;<xref rid="Fig8" ref-type="fig">8</xref>) showed a biphasic linear regression fit to losartan dosage. The ascending limb of the regression reflects the dosage increase from 25&#xA0;mg/day in the cold early part of the year, to 50&#xA0;mg/day in the less cold late part of the year. The descending limb of the regression reflects the decreasing requirement during the summer months.<fig id="Fig7"><label>Figure&#xA0;7</label><caption><p>Daily values for SBP, DBP, and losartan dosages for the year 2007, as a function of the corresponding maximum environmental temperatures. Least-squares regression fits (third order polynomial) to the points are shown as <italic>continuous lines</italic> (<italic>red</italic> for losartan dosage). This is a re-plot of the data of Figure&#xA0;<xref rid="Fig3" ref-type="fig">3</xref>.</p></caption><graphic xlink:href="13104_2015_1215_Fig7_HTML" id="MO7"/></fig><fig id="Fig8"><label>Figure&#xA0;8</label><caption><p>Daily values for SBP, DBP, and losartan dosages for the year 2011, as a function of the corresponding maximum environmental temperatures. Least-squares regression fits (third order polynomial) to the points are shown as <italic>continuous lines</italic>. This is a re-plot of the data of Figure&#xA0;<xref rid="Fig5" ref-type="fig">5</xref>.</p></caption><graphic xlink:href="13104_2015_1215_Fig8_HTML" id="MO8"/></fig></p>
        <p>Figure&#xA0;<xref rid="Fig9" ref-type="fig">9</xref> shows regression plots for the entire 2003&#x2013;2014 period. The curves were essentially horizontal for 2003&#x2013;2009. Thus, dosage was independent of temperature. In 2010 came the first indication of the extreme seasonal influence&#x2014;explicit from 2012 onwards. Indeed, by extrapolation, under these conditions losartan could have been abandoned at around 34&#xB0;C.<fig id="Fig9"><label>Figure&#xA0;9</label><caption><p>Relationship between daily losartan requirements for the 2003-2014 period and corresponding maximum environmental temperatures. The third order regressions through data points (e.g. Figures&#xA0;<xref rid="Fig7" ref-type="fig">7</xref>, <xref rid="Fig8" ref-type="fig">8</xref>) are shown for each year. <italic>Line colouring</italic> for different years follows that of Figure&#xA0;<xref rid="Fig6" ref-type="fig">6</xref>. Consecutive r<sup>2</sup> values for 2011&#x2013;2014 were 0.22, 0.38, 0.34, and 0.45.</p></caption><graphic xlink:href="13104_2015_1215_Fig9_HTML" id="MO9"/></fig></p>
      </sec>
    </sec>
    <sec id="Sec10" sec-type="discussion">
      <title>Discussion</title>
      <p>The present study arose from the belief that an interference with physiological homeostatic controls, which was deemed necessary for management of primary hypertension, would require close BP assessment&#x2014;an assessment which would be facilitated by the digital devices that had become available for home-monitoring. Whether it is the actual BP level, or variation in that level, that is most responsible for adverse clinical consequences, is much debated [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR22">22</xref>]. Here, the day-to-day adjustment of losartan dosage to observed <italic>daily</italic> BP levels would seem to address both factors.</p>
      <sec id="Sec11">
        <title>Angiotensin II receptors</title>
        <p>Antihypertensive, dosage-dependent, effects of losartan were evident in early short-term studies with both normal volunteers and patients [<xref ref-type="bibr" rid="CR23">23</xref>]. Thus, Gottlieb et al. [<xref ref-type="bibr" rid="CR24">24</xref>] noted in 1993 that vascular dilation and BP-lowering effects were maximal with 25&#xA0;mg/day and <italic>declined</italic> at higher doses, whereas effects deemed &#x2018;neurohormonal,&#x2019; such as increased levels of renin and of the circulating angiotensin II octapeptide (Ang II), continued to increase at higher concentrations. With the present subject, summer losartan hypersensitivity became most evident when dosage increased from around 25 to 50&#xA0;mg/day, consistent with a neurohormonal influence.</p>
        <p>Cell surface Ang II receptors (subtypes AT<sub>1</sub>R and AT<sub>2</sub>R) are present in various mammalian species. It is the reaction of Ang II with AT<sub>1</sub>R, the dominant high-affinity receptor, that is blocked with high specificity by losartan [<xref ref-type="bibr" rid="CR25">25</xref>]. Independently of losartan, the reaction normally triggers G<sub>q</sub>-protein signalling that mobilises intracellular Ca<sup>++</sup>, resulting in increased vascular tone. Such signalling is itself susceptible to modulation by regulatory factors&#x2014;such as Regulator of G-Protein Signaling-2 (RGS-2) [<xref ref-type="bibr" rid="CR18">18</xref>&#x2013;<xref ref-type="bibr" rid="CR20">20</xref>]&#x2014;which are themselves subject to regulatory inputs. So determining how seasonal factors feed into this system, and whether the key seasonal factor is, indeed, temperature [<xref ref-type="bibr" rid="CR11">11</xref>, <xref ref-type="bibr" rid="CR26">26</xref>], are unlikely to be easy.</p>
        <p>Although bound to plasma albumin, losartan itself is rapidly degraded to a longer-lived, pharmacologically more potent, carboxylic acid derivative, also bound to albumin; this sustains AT<sub>1</sub>R blockade non-competitively for many hours [<xref ref-type="bibr" rid="CR27">27</xref>, <xref ref-type="bibr" rid="CR28">28</xref>]. Thus, provided a sufficient dose is employed, and the period between doses is not too long, successive losartan doses may act cumulatively. This is consistent with the observation that, in the <italic>spring</italic> of 2000, following the implementation, and then cessation, of losartan therapy, BP values fell progressively, and rose progressively, each over several days (Figure&#xA0;<xref rid="Fig1" ref-type="fig">1</xref>). However, when losartan was restarted in the <italic>summer</italic> of 2002, the fall was immediate. This hinted at an additional seasonal influence, <italic>conditional</italic> on losartan dosage that would be uncovered (&#x201C;unmasked&#x201D;) in later years (Figures&#xA0;<xref rid="Fig6" ref-type="fig">6</xref>, <xref rid="Fig9" ref-type="fig">9</xref>).</p>
      </sec>
      <sec id="Sec12">
        <title>Unmasking of angiotensin II subtype 2 receptors</title>
        <p>Treatment with ACE inhibitors <italic>lowers</italic> the circulating concentration of Ang II, so decreasing its reaction with the dominant AT<sub>1</sub>R subtype, and thus lowering BP. However, the <italic>increase</italic> in the circulating concentration of Ang II, following blockage of the AT<sub>1</sub>R subtype with losartan, should suffice to affect the losartan-insensitive, low abundance, AT<sub>2</sub>R subtype. Activation of AT<sub>2</sub>R usually <italic>counteracts</italic> the effects of AT<sub>1</sub>R activation (e.g. vasodilation not vasoconstriction) [<xref ref-type="bibr" rid="CR29">29</xref>, <xref ref-type="bibr" rid="CR30">30</xref>]. It is reported for hypertension-prone rats that Ang II will cause AT<sub>2</sub>R-mediated vasodilation, <italic>provided</italic> AT<sub>1</sub>R is blocked and AT<sub>2</sub>R expression is upregulated [<xref ref-type="bibr" rid="CR31">31</xref>, <xref ref-type="bibr" rid="CR32">32</xref>]. Thus, activation of AT<sub>2</sub>R is <italic>conditional</italic>, and is described as being &#x201C;unmasked&#x201D; or &#x201C;trumped&#x201D; when AT<sub>1</sub>R-mediated effects are inhibited by agents such as losartan [<xref ref-type="bibr" rid="CR33">33</xref>&#x2013;<xref ref-type="bibr" rid="CR35">35</xref>]. Indeed, Abdulla and Johns [<xref ref-type="bibr" rid="CR36">36</xref>] recently reported for rats that losartan increased the fall in BP following the AT<sub>2</sub>R receptor-associated inhibition of renal sympathetic nerve activity, which was part of the homeostatic response to total body fluid volume expansion, such as normally occurs in humans in summertime [<xref ref-type="bibr" rid="CR37">37</xref>]. They concluded that: &#x201C;The basal level of central AT<sub>2</sub> receptor activation is not involved in the normal renal sympatho-inhibition due to volume expansion, unless the counter-regulatory AT<sub>1</sub> receptors are blocked&#x201D;. Thus, there is again an &#x201C;unmasking&#x201D; effect of losartan. These conclusions from rodents are supported by studies of Bartter and Gitelman syndromes (BS/GS) patients, where there is endogenous antagonism of AT<sub>1</sub>R signalling that in many respects resemble inhibition by losartan (e.g. Ang II elevation) [<xref ref-type="bibr" rid="CR38">38</xref>, <xref ref-type="bibr" rid="CR39">39</xref>].</p>
      </sec>
      <sec id="Sec13">
        <title>Hypothesis</title>
        <p>A working hypothesis, consistent with animal experiments and BS/GS studies, is that under conditions of heat-stress (e.g. vascular dilation, salt loss), there is increased expression of a countervailing, losartan-insensitive, receptor subtype (AT<sub>2</sub>R). By <italic>lowering</italic> BP in response to antiotensin-II, AT<sub>2</sub>R would facilitate fine-tuning of the AT<sub>1</sub>R-mediated vasoconstriction that supports BP when superficial veins dilate to enhance body cooling. This AT<sub>2</sub>R activity might be sufficient to explain a small summertime BP dip found in normal human subjects whose Ang II levels are not increased (Figure&#xA0;<xref rid="Fig2" ref-type="fig">2</xref>). The dip would be greatly enhanced when Ang II levels are increased at higher losartan dosages. Under this condition, the excess of Ang II would be expected to react with the AT<sub>2</sub>R, so greatly amplifying the losartan-induced fall in BP. To this extent, the present human study is supportive of most rodent and BS/GS studies. The hypothesis predicts that summertime dips would be decreased either by ACE inhibitors, or by AT<sub>2</sub>R antagonists, such as EMA401 [<xref ref-type="bibr" rid="CR40">40</xref>]. Indeed, the study of benazepril by Chen et al. [<xref ref-type="bibr" rid="CR15">15</xref>] supports the hypothesis&#xA0;and is in keeping with the recommended caution regarding combination therapy with ACE inhibitors and ARBs [<xref ref-type="bibr" rid="CR41">41</xref>]. AT<sub>2</sub>R agonists, including truncated Ang II fragments, are possible novel antihypertensive agents [<xref ref-type="bibr" rid="CR34">34</xref>].</p>
      </sec>
      <sec id="Sec14">
        <title>Night-time dipping</title>
        <p>ABP recordings often reveal a small dip in BP values when subjects are resting at night. Although carried out on biased groups (members of different summer and winter populations that had been selected to attend hypertension clinics), ABP studies in Italy [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR3">3</xref>] found that, in summertime, night-time dipping was less evident and SBPs were slightly <italic>increased</italic>; it was only with day-time BP measurements that the summertime decrease was evident. The night-time SBP increase was particularly apparent in elderly subjects receiving antihypertensive medication (type not specified). While noting that &#x201C;milder sleep problems associated with hot weather cannot be completely excluded&#x201D; [<xref ref-type="bibr" rid="CR3">3</xref>], and that there may be &#x201C;different sleeping behaviors between summer and winter&#x201D; [<xref ref-type="bibr" rid="CR2">2</xref>], the authors suggested that there is often a, clinic-directed or self-directed, reduction in medication in summertime, either because of a measured daytime lowering of BP, or because it is &#x201C;common knowledge&#x201D; that such lowering would have occurred [<xref ref-type="bibr" rid="CR2">2</xref>]. Thus, those who would reduce the number of medications, or reduce dosages (as in the present study), were cautioned by Modesti et al. [<xref ref-type="bibr" rid="CR3">3</xref>] that &#x201C;the results of our study clearly indicate that the practice of reducing treatment in the summer in the elderly based on low clinic BP values is not good, because it might be responsible for a potentially dangerous increase in night BP&#x201D;.</p>
        <p>Nevertheless, given that hypertension-related adverse cardiovascular events are less in summer, then correcting, at this time of the year, for the daytime <italic>decrease</italic> in SBP, may be more important that correcting for a night-time <italic>increase</italic>. Determining the swings and roundabouts of this is a matter for future study, but a prudent interim measure might be to take some or all of whatever medications are deemed necessary in hot weather, late in the evening. Such a season-tailored &#x2018;chronotherapeutic approach&#x2019; [<xref ref-type="bibr" rid="CR12">12</xref>,&#xA0;<xref ref-type="bibr" rid="CR42">42</xref>] touches on the issue of the period of bioavailability of a medication after ingestion (as discussed above [<xref ref-type="bibr" rid="CR27">27</xref>, <xref ref-type="bibr" rid="CR28">28</xref>]).</p>
      </sec>
    </sec>
    <sec id="Sec15" sec-type="conclusion">
      <title>Conclusions</title>
      <p>There should be greater awareness that the inflection points on J-curves [<xref ref-type="bibr" rid="CR43">43</xref>] might vary on a seasonal basis. This awareness should encourage close self-monitoring of BP, with appropriate adjustment of medication dosage, especially in the case of losartan. Such dosage adjustment may be necessary for those living in, or travelling to, geographical regions where temperatures are seasonally or continually high. Assuming temperature to be primary, then this caveat might also apply to those engaging in hot activities (e.g. Turkish baths, hot yoga). More comprehensive softwares in BP monitoring devises might take into account both environmental temperatures and recent BP readings, and automatically recommend daily medication adjustment. Although randomized, double-blind, trials, may sometimes lead to proposals for increases in losartan dosages (e.g. Konstam et al. [<xref ref-type="bibr" rid="CR44">44</xref>] advise elevation from 50 to 150&#xA0;mg), it would seem that the climate of the country where such trials had taken place should be considered when assessing the risk-benefits of such regimens. Indeed, hypertension has been invoked as a factor explaining higher mortality in cold climates [<xref ref-type="bibr" rid="CR45">45</xref>]. Sadly, studies of ARB-induced hypotension and AKI, both in the elderly [<xref ref-type="bibr" rid="CR46">46</xref>], and in diabetic patients [<xref ref-type="bibr" rid="CR47">47</xref>], give little weight to seasonal factors and dosage variation. An association of medication-induced hypotension with cognitive impairment in the elderly has led to disparagement of &#x201C;one size fits all&#x201D; approaches to therapy [<xref ref-type="bibr" rid="CR48">48</xref>]. Finally, as noted by Verberk et al. [<xref ref-type="bibr" rid="CR49">49</xref>] there may be direct economic benefits to health care systems if excessive dosages of costly medications are avoided.</p>
    </sec>
    <sec id="Sec16">
      <title>Endnotes</title>
      <p><sup>a</sup> This paper is dedicated to W. Stanley Peart and James F. Mowbray, whose mentorship in times long past guided me to the road &#x2018;less travelled by&#x2019;.</p>
      <p><sup>b</sup> The office of David J. Hemings.</p>
    </sec>
  </body>
  <back>
    <ack>
      <title>Author&#x2019;s contributions</title>
      <p>Donald Forsdyke is responsible for all aspects of this paper.</p>
      <sec id="d30e955">
        <title>Compliance with ethical guidelines</title>
        <p><bold>Competing interests</bold> The author declares that he has no competing interests.</p>
      </sec>
    </ack>
    <ref-list id="Bib1">
      <title>References</title>
      <ref id="CR1">
        <label>1.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Charach</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Rabinovich</surname>
              <given-names>PD</given-names>
            </name>
            <name>
              <surname>Weintraub</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Seasonal changes in blood pressure and frequency of related complications in elderly Israeli patients with essential hypertension</article-title>
          <source>Gerontol</source>
          <year>2004</year>
          <volume>50</volume>
          <fpage>315</fpage>
          <lpage>321</lpage>
          <pub-id pub-id-type="doi">10.1159/000079130</pub-id>
        </element-citation>
      </ref>
      <ref id="CR2">
        <label>2.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Fedecostante</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Barbatelli</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Guerra</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Espinosa</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Dess&#x131;-Fulgheri</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Sarzani</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
          <article-title>Summer does not always mean lower: seasonality of 24&#xA0;h, daytime, and night-time blood pressure</article-title>
          <source>J Hypertens</source>
          <year>2012</year>
          <volume>30</volume>
          <fpage>1392</fpage>
          <lpage>1398</lpage>
          <pub-id pub-id-type="doi">10.1097/HJH.0b013e328354668a</pub-id>
          <pub-id pub-id-type="pmid">22595956</pub-id>
        </element-citation>
      </ref>
      <ref id="CR3">
        <label>3.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Modesti</surname>
              <given-names>PA</given-names>
            </name>
            <name>
              <surname>Morabito</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Bertolozzi</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Massetti</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Panci</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Lumachi</surname>
              <given-names>C</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Weather-related changes in 24-h blood pressure profile: effects of age and implications for hypertension management</article-title>
          <source>Hypertension</source>
          <year>2006</year>
          <volume>47</volume>
          <fpage>155</fpage>
          <lpage>161</lpage>
          <pub-id pub-id-type="doi">10.1161/01.HYP.0000199192.17126.d4</pub-id>
          <pub-id pub-id-type="pmid">16380524</pub-id>
        </element-citation>
      </ref>
      <ref id="CR4">
        <label>4.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lewington</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Li</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Sherliker</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Guo</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Millwood</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Bian</surname>
              <given-names>Z</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Seasonal variation in blood pressure and its relationship with outdoor temperature in 10 diverse regions of China: the China Kadoorie Biobank</article-title>
          <source>J Hypertens</source>
          <year>2012</year>
          <volume>30</volume>
          <fpage>1383</fpage>
          <lpage>1391</lpage>
          <pub-id pub-id-type="doi">10.1097/HJH.0b013e32835465b5</pub-id>
          <pub-id pub-id-type="pmid">22688260</pub-id>
        </element-citation>
      </ref>
      <ref id="CR5">
        <label>5.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Modesti</surname>
              <given-names>PA</given-names>
            </name>
          </person-group>
          <article-title>Season, temperature and blood pressure: a complex interaction</article-title>
          <source>Eur J Int Med</source>
          <year>2013</year>
          <volume>24</volume>
          <fpage>604</fpage>
          <lpage>607</lpage>
          <pub-id pub-id-type="doi">10.1016/j.ejim.2013.08.002</pub-id>
        </element-citation>
      </ref>
      <ref id="CR6">
        <label>6.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hozawa</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Kuriyama</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Shimazu</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Ohmori-Matsuda</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Tsuji</surname>
              <given-names>I</given-names>
            </name>
          </person-group>
          <article-title>Seasonal variation in home blood pressure measurements and relation to outside temperature in Japan</article-title>
          <source>Clin Exp Hypertens</source>
          <year>2011</year>
          <volume>33</volume>
          <fpage>153</fpage>
          <lpage>158</lpage>
          <pub-id pub-id-type="doi">10.3109/10641963.2010.531841</pub-id>
          <pub-id pub-id-type="pmid">21271816</pub-id>
        </element-citation>
      </ref>
      <ref id="CR7">
        <label>7.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Aubini&#xE8;re-Robb</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Jeemon</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Hastie</surname>
              <given-names>CE</given-names>
            </name>
            <name>
              <surname>Patel</surname>
              <given-names>RK</given-names>
            </name>
            <name>
              <surname>McCallum</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Morrison</surname>
              <given-names>LD</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Blood pressure response to patterns of weather fluctuations and effect on mortality</article-title>
          <source>Hypertension</source>
          <year>2013</year>
          <volume>62</volume>
          <fpage>190</fpage>
          <lpage>196</lpage>
          <pub-id pub-id-type="doi">10.1161/HYPERTENSIONAHA.111.00686</pub-id>
          <pub-id pub-id-type="pmid">23648702</pub-id>
        </element-citation>
      </ref>
      <ref id="CR8">
        <label>8.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Tu</surname>
              <given-names>Y-K</given-names>
            </name>
            <name>
              <surname>Chien</surname>
              <given-names>K-L</given-names>
            </name>
            <name>
              <surname>Chiu</surname>
              <given-names>Y-W</given-names>
            </name>
            <name>
              <surname>Ellison</surname>
              <given-names>GTH</given-names>
            </name>
          </person-group>
          <article-title>Seasonal variation in blood pressure is modulated by gender and age but not by BMI in a large Taiwanese population, 1996&#x2013;2006</article-title>
          <source>J Am Soc Hypertens</source>
          <year>2013</year>
          <volume>7</volume>
          <fpage>216</fpage>
          <lpage>228</lpage>
          <pub-id pub-id-type="doi">10.1016/j.jash.2013.01.008</pub-id>
          <pub-id pub-id-type="pmid">23490614</pub-id>
        </element-citation>
      </ref>
      <ref id="CR9">
        <label>9.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Floras</surname>
              <given-names>JS</given-names>
            </name>
          </person-group>
          <article-title>Blood pressure variability: a novel and important risk factor</article-title>
          <source>Can J Cardiol</source>
          <year>2013</year>
          <volume>29</volume>
          <fpage>557</fpage>
          <lpage>563</lpage>
          <pub-id pub-id-type="doi">10.1016/j.cjca.2013.02.012</pub-id>
          <pub-id pub-id-type="pmid">23618505</pub-id>
        </element-citation>
      </ref>
      <ref id="CR10">
        <label>10.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Messerli</surname>
              <given-names>FH</given-names>
            </name>
            <name>
              <surname>Williams</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Ritz</surname>
              <given-names>E</given-names>
            </name>
          </person-group>
          <article-title>Essential hypertension</article-title>
          <source>Lancet</source>
          <year>2007</year>
          <volume>370</volume>
          <fpage>591</fpage>
          <lpage>603</lpage>
          <pub-id pub-id-type="doi">10.1016/S0140-6736(07)61299-9</pub-id>
          <pub-id pub-id-type="pmid">17707755</pub-id>
        </element-citation>
      </ref>
      <ref id="CR11">
        <label>11.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Modesti</surname>
              <given-names>PA</given-names>
            </name>
            <name>
              <surname>Morabito</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Massetti</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Rapi</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Orlandini</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Mancia</surname>
              <given-names>G</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Seasonal blood pressure changes. An independent relationship with temperature and daylight hours</article-title>
          <source>Hypertension</source>
          <year>2013</year>
          <volume>61</volume>
          <fpage>908</fpage>
          <lpage>914</lpage>
          <pub-id pub-id-type="doi">10.1161/HYPERTENSIONAHA.111.00315</pub-id>
          <pub-id pub-id-type="pmid">23381792</pub-id>
        </element-citation>
      </ref>
      <ref id="CR12">
        <label>12.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Cuspidi</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Ochoa</surname>
              <given-names>JE</given-names>
            </name>
            <name>
              <surname>Parati</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
          <article-title>Seasonal variations in blood pressure: a complex phenomenon</article-title>
          <source>J Hypertens</source>
          <year>2012</year>
          <volume>30</volume>
          <fpage>1315</fpage>
          <lpage>1320</lpage>
          <pub-id pub-id-type="doi">10.1097/HJH.0b013e328355d7f9</pub-id>
          <pub-id pub-id-type="pmid">22706390</pub-id>
        </element-citation>
      </ref>
      <ref id="CR13">
        <label>13.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Tomlinson</surname>
              <given-names>LA</given-names>
            </name>
            <name>
              <surname>Abel</surname>
              <given-names>GA</given-names>
            </name>
            <name>
              <surname>Chaudhry</surname>
              <given-names>AN</given-names>
            </name>
            <name>
              <surname>Tomson</surname>
              <given-names>CR</given-names>
            </name>
            <name>
              <surname>Wilkinson</surname>
              <given-names>IB</given-names>
            </name>
            <name>
              <surname>Roland</surname>
              <given-names>MO</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>ACE inhibitor and angiotensin-II receptor antagonist prescribing and hospital admissions with acute kidney injury: a longitudinal ecological study</article-title>
          <source>PLoS One</source>
          <year>2013</year>
          <volume>8</volume>
          <fpage>e78465</fpage>
          <pub-id pub-id-type="doi">10.1371/journal.pone.0078465</pub-id>
          <pub-id pub-id-type="pmid">24223154</pub-id>
        </element-citation>
      </ref>
      <ref id="CR14">
        <label>14.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Handler</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>Seasonal variability of blood pressure in California</article-title>
          <source>J Clin Hypert</source>
          <year>2011</year>
          <volume>50</volume>
          <fpage>856</fpage>
          <lpage>860</lpage>
          <pub-id pub-id-type="doi">10.1111/j.1751-7176.2011.00537.x</pub-id>
        </element-citation>
      </ref>
      <ref id="CR15">
        <label>15.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Chen</surname>
              <given-names>Q</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Tian</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Tang</surname>
              <given-names>X</given-names>
            </name>
            <name>
              <surname>Yu</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Marshall</surname>
              <given-names>RJ</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Association between ambient temperature and blood pressure and blood pressure regulators: 1831 hypertensive patients followed up for 3&#xA0;years</article-title>
          <source>PLoS One</source>
          <year>2013</year>
          <volume>8</volume>
          <issue>12</issue>
          <fpage>e84522</fpage>
          <pub-id pub-id-type="doi">10.1371/journal.pone.0084522</pub-id>
          <pub-id pub-id-type="pmid">24391962</pub-id>
        </element-citation>
      </ref>
      <ref id="CR16">
        <label>16.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mancia</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Grassi</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
          <article-title>Aggressive blood pressure lowering is dangerous: the J-curve: pro side of the argument</article-title>
          <source>Hypertension</source>
          <year>2014</year>
          <volume>63</volume>
          <fpage>29</fpage>
          <lpage>36</lpage>
          <pub-id pub-id-type="doi">10.1161/HYPERTENSIONAHA.113.01922</pub-id>
          <pub-id pub-id-type="pmid">24336629</pub-id>
        </element-citation>
      </ref>
      <ref id="CR17">
        <label>17.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Forsdyke</surname>
              <given-names>DR</given-names>
            </name>
          </person-group>
          <article-title>Seasonal dosage-dependent hypersensitivity to the angiotensin II receptor blocker, losartan: a case report and review</article-title>
          <source>PeerJ PrePrints</source>
          <year>2013</year>
          <volume>1</volume>
          <fpage>e144v1</fpage>
        </element-citation>
      </ref>
      <ref id="CR18">
        <label>18.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Siderovski</surname>
              <given-names>DP</given-names>
            </name>
            <name>
              <surname>Heximer</surname>
              <given-names>SP</given-names>
            </name>
            <name>
              <surname>Forsdyke</surname>
              <given-names>DR</given-names>
            </name>
          </person-group>
          <article-title>A human gene encoding a putative basic helix-loop-helix phosphoprotein whose messenger-RNA increases rapidly in cycloheximide-treated blood mononuclear cells</article-title>
          <source>DNA Cell Biol</source>
          <year>1994</year>
          <volume>13</volume>
          <fpage>125</fpage>
          <lpage>147</lpage>
          <pub-id pub-id-type="doi">10.1089/dna.1994.13.125</pub-id>
          <pub-id pub-id-type="pmid">8179820</pub-id>
        </element-citation>
      </ref>
      <ref id="CR19">
        <label>19.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Tang</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Lu</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Karas</surname>
              <given-names>RH</given-names>
            </name>
            <name>
              <surname>Aronovitz</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Heximer</surname>
              <given-names>SP</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Regulator of G-protein signaling-2 mediates vascular smooth muscle relaxation and blood pressure</article-title>
          <source>Nat Med</source>
          <year>2003</year>
          <volume>9</volume>
          <fpage>1506</fpage>
          <lpage>1512</lpage>
          <pub-id pub-id-type="doi">10.1038/nm958</pub-id>
          <pub-id pub-id-type="pmid">14608379</pub-id>
        </element-citation>
      </ref>
      <ref id="CR20">
        <label>20.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Cal&#xF2;</surname>
              <given-names>LA</given-names>
            </name>
            <name>
              <surname>Pagnin</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Davis</surname>
              <given-names>PA</given-names>
            </name>
            <name>
              <surname>Sartori</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Ceolotto</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Pessina</surname>
              <given-names>AC</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Increased expression of regulator of G protein signaling-2 (RGS-2) in Bartter&#x2019;s/Gitelman&#x2019;s syndrome. A role in the control of vascular tone and implication for hypertension</article-title>
          <source>J Clin Endocrinol Metab</source>
          <year>2004</year>
          <volume>89</volume>
          <fpage>4153</fpage>
          <lpage>4157</lpage>
          <pub-id pub-id-type="doi">10.1210/jc.2004-0498</pub-id>
          <pub-id pub-id-type="pmid">15292363</pub-id>
        </element-citation>
      </ref>
      <ref id="CR21">
        <label>21.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Tracey</surname>
              <given-names>KJ</given-names>
            </name>
          </person-group>
          <article-title>Hypertension: an immune disorder?</article-title>
          <source>Immunity</source>
          <year>2014</year>
          <volume>41</volume>
          <fpage>673</fpage>
          <lpage>674</lpage>
          <pub-id pub-id-type="doi">10.1016/j.immuni.2014.11.007</pub-id>
          <pub-id pub-id-type="pmid">25517606</pub-id>
        </element-citation>
      </ref>
      <ref id="CR22">
        <label>22.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Schutte</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Thijs</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Liu</surname>
              <given-names>Y-P</given-names>
            </name>
            <name>
              <surname>Asayama</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Jin</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Odili</surname>
              <given-names>A</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Within-subject blood pressure level, not variability, predicts fatal and nonfatal outcomes in a general population</article-title>
          <source>Hypertension</source>
          <year>2012</year>
          <volume>60</volume>
          <fpage>1138</fpage>
          <lpage>1147</lpage>
          <pub-id pub-id-type="doi">10.1161/HYPERTENSIONAHA.112.202143</pub-id>
          <pub-id pub-id-type="pmid">23071126</pub-id>
        </element-citation>
      </ref>
      <ref id="CR23">
        <label>23.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Christen</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Waeber</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Nussberger</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Porchet</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Borland</surname>
              <given-names>RM</given-names>
            </name>
            <name>
              <surname>Lee</surname>
              <given-names>RJ</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Oral administration of DuP 753, a specific angiotensin II receptor antagonist, to normal male volunteers. Inhibition of pressor response to exogenous angiotensin I and II</article-title>
          <source>Circulation</source>
          <year>1991</year>
          <volume>83</volume>
          <fpage>1333</fpage>
          <lpage>1342</lpage>
          <pub-id pub-id-type="doi">10.1161/01.CIR.83.4.1333</pub-id>
          <pub-id pub-id-type="pmid">2013151</pub-id>
        </element-citation>
      </ref>
      <ref id="CR24">
        <label>24.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gottlieb</surname>
              <given-names>SS</given-names>
            </name>
            <name>
              <surname>Dickstein</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Fleck</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Kostis</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Levine</surname>
              <given-names>TB</given-names>
            </name>
            <name>
              <surname>LeJemtel</surname>
              <given-names>T</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Hemodynamic and neurohormonal effects of the angiotensin II antagonist losartan in patients with congestive heart failure</article-title>
          <source>Circulation</source>
          <year>1993</year>
          <volume>88</volume>
          <fpage>1602</fpage>
          <lpage>1609</lpage>
          <pub-id pub-id-type="doi">10.1161/01.CIR.88.4.1602</pub-id>
          <pub-id pub-id-type="pmid">8403307</pub-id>
        </element-citation>
      </ref>
      <ref id="CR25">
        <label>25.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wong</surname>
              <given-names>PC</given-names>
            </name>
            <name>
              <surname>Barnes</surname>
              <given-names>TB</given-names>
            </name>
            <name>
              <surname>Chiu</surname>
              <given-names>AT</given-names>
            </name>
            <name>
              <surname>Christ</surname>
              <given-names>DD</given-names>
            </name>
            <name>
              <surname>Duncia</surname>
              <given-names>JV</given-names>
            </name>
            <name>
              <surname>Herblin</surname>
              <given-names>WF</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Losartan (DuP 753), an orally active nonpeptide angiotensin II receptor antagonist</article-title>
          <source>Cardiovasc Drug Rev</source>
          <year>1991</year>
          <volume>9</volume>
          <fpage>317</fpage>
          <lpage>339</lpage>
          <pub-id pub-id-type="doi">10.1111/j.1527-3466.1991.tb00419.x</pub-id>
        </element-citation>
      </ref>
      <ref id="CR26">
        <label>26.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Schwartz</surname>
              <given-names>BG</given-names>
            </name>
            <name>
              <surname>Kloner</surname>
              <given-names>RA</given-names>
            </name>
          </person-group>
          <article-title>Seasonal variation in cardiac death rates is uniform across different climates</article-title>
          <source>Circulation</source>
          <year>2012</year>
          <volume>126</volume>
          <fpage>A11723</fpage>
        </element-citation>
      </ref>
      <ref id="CR27">
        <label>27.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Munafo</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Christen</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Nussberger</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Shum</surname>
              <given-names>LY</given-names>
            </name>
            <name>
              <surname>Borland</surname>
              <given-names>RM</given-names>
            </name>
            <name>
              <surname>Lee</surname>
              <given-names>RJ</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Drug concentration response relationships in normal volunteers after oral administration of losartan, an angiotensin II receptor antagonist</article-title>
          <source>Clin Pharmacol Ther</source>
          <year>1992</year>
          <volume>51</volume>
          <fpage>513</fpage>
          <lpage>521</lpage>
          <pub-id pub-id-type="doi">10.1038/clpt.1992.56</pub-id>
          <pub-id pub-id-type="pmid">1587065</pub-id>
        </element-citation>
      </ref>
      <ref id="CR28">
        <label>28.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lo</surname>
              <given-names>M-W</given-names>
            </name>
            <name>
              <surname>Goldberg</surname>
              <given-names>MR</given-names>
            </name>
            <name>
              <surname>McCrea</surname>
              <given-names>JB</given-names>
            </name>
            <name>
              <surname>Lu</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Furtek</surname>
              <given-names>CI</given-names>
            </name>
            <name>
              <surname>Bjornsson</surname>
              <given-names>TD</given-names>
            </name>
          </person-group>
          <article-title>Pharmacokinetics of losartan, an angiotensin II receptor antagonist, and its active metabolite EXP3 174 in humans</article-title>
          <source>Clin Pharmacol Ther</source>
          <year>1995</year>
          <volume>58</volume>
          <fpage>641</fpage>
          <lpage>649</lpage>
          <pub-id pub-id-type="doi">10.1016/0009-9236(95)90020-9</pub-id>
          <pub-id pub-id-type="pmid">8529329</pub-id>
        </element-citation>
      </ref>
      <ref id="CR29">
        <label>29.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Matsubara</surname>
              <given-names>H</given-names>
            </name>
          </person-group>
          <article-title>Pathophysiological role of angiotensin II type 2 receptor in cardiovascular and renal diseases</article-title>
          <source>Circ Res</source>
          <year>1998</year>
          <volume>83</volume>
          <fpage>1182</fpage>
          <lpage>1191</lpage>
          <pub-id pub-id-type="doi">10.1161/01.RES.83.12.1182</pub-id>
          <pub-id pub-id-type="pmid">9851935</pub-id>
        </element-citation>
      </ref>
      <ref id="CR30">
        <label>30.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>de Gasparo</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Catt</surname>
              <given-names>KJ</given-names>
            </name>
            <name>
              <surname>Inagami</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Wright</surname>
              <given-names>JW</given-names>
            </name>
            <name>
              <surname>Unger</surname>
              <given-names>T</given-names>
            </name>
          </person-group>
          <article-title>International Union of Pharmacology. XXIII. The Angiotensin II Receptors</article-title>
          <source>Pharm Rev</source>
          <year>2000</year>
          <volume>52</volume>
          <fpage>415</fpage>
          <lpage>472</lpage>
          <pub-id pub-id-type="pmid">10977869</pub-id>
        </element-citation>
      </ref>
      <ref id="CR31">
        <label>31.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Cosentino</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Savoia</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>De Paolis</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Francia</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Russo</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Maffei</surname>
              <given-names>A</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Angiotensin II type 2 receptors contribute to vascular responses in spontaneously hypertensive rats treated with angiotensin II type 1 receptor antagonists</article-title>
          <source>Am J Hypertens</source>
          <year>2005</year>
          <volume>18</volume>
          <fpage>493</fpage>
          <lpage>499</lpage>
          <pub-id pub-id-type="doi">10.1016/j.amjhyper.2004.11.007</pub-id>
          <pub-id pub-id-type="pmid">15831358</pub-id>
        </element-citation>
      </ref>
      <ref id="CR32">
        <label>32.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Savoia</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Tabet</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Yao</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Schiffrin</surname>
              <given-names>EL</given-names>
            </name>
            <name>
              <surname>Touyz</surname>
              <given-names>RM</given-names>
            </name>
          </person-group>
          <article-title>Negative regulation of Rho/Rho kinase by angiotensin II type 2 receptor in vascular smooth muscle cells: role in angiotensin II&#x2013;induced vasodilation</article-title>
          <source>J Hypertens</source>
          <year>2005</year>
          <volume>23</volume>
          <fpage>1037</fpage>
          <lpage>1045</lpage>
          <pub-id pub-id-type="doi">10.1097/01.hjh.0000166845.49850.39</pub-id>
          <pub-id pub-id-type="pmid">15834290</pub-id>
        </element-citation>
      </ref>
      <ref id="CR33">
        <label>33.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Li</surname>
              <given-names>XC</given-names>
            </name>
            <name>
              <surname>Widdop</surname>
              <given-names>RE</given-names>
            </name>
          </person-group>
          <article-title>AT2 receptor-mediated vasodilatation is unmasked by AT1 receptor blockade in conscious SHR</article-title>
          <source>Brit J Pharm</source>
          <year>2004</year>
          <volume>142</volume>
          <fpage>821</fpage>
          <lpage>830</lpage>
          <pub-id pub-id-type="doi">10.1038/sj.bjp.0705838</pub-id>
        </element-citation>
      </ref>
      <ref id="CR34">
        <label>34.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>McCarthy</surname>
              <given-names>CA</given-names>
            </name>
            <name>
              <surname>Widdop</surname>
              <given-names>RE</given-names>
            </name>
            <name>
              <surname>Denton</surname>
              <given-names>KM</given-names>
            </name>
            <name>
              <surname>Jones</surname>
              <given-names>ES</given-names>
            </name>
          </person-group>
          <article-title>Update on the angiotensin AT<sub>2</sub> receptor</article-title>
          <source>Curr Hypertens Rep</source>
          <year>2013</year>
          <volume>15</volume>
          <fpage>25</fpage>
          <lpage>30</lpage>
          <pub-id pub-id-type="doi">10.1007/s11906-012-0321-4</pub-id>
          <pub-id pub-id-type="pmid">23224511</pub-id>
        </element-citation>
      </ref>
      <ref id="CR35">
        <label>35.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Schalekamp</surname>
              <given-names>MADH</given-names>
            </name>
            <name>
              <surname>Danser</surname>
              <given-names>AHJ</given-names>
            </name>
          </person-group>
          <article-title>How does the angiotensin II type 1 receptor &#x2018;trump&#x2019;the type 2 receptor in blood pressure control?</article-title>
          <source>J Hypertens</source>
          <year>2013</year>
          <volume>31</volume>
          <fpage>705</fpage>
          <lpage>712</lpage>
          <pub-id pub-id-type="doi">10.1097/HJH.0b013e32835d6d11</pub-id>
          <pub-id pub-id-type="pmid">23325393</pub-id>
        </element-citation>
      </ref>
      <ref id="CR36">
        <label>36.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Abdulla</surname>
              <given-names>MH</given-names>
            </name>
            <name>
              <surname>Johns</surname>
              <given-names>EJ</given-names>
            </name>
          </person-group>
          <article-title>Role of angiotensin AT2 receptors and nitric oxide in the cardiopulmonary baroreflex control of renal sympathetic nerve activity in rats</article-title>
          <source>J Hypertens</source>
          <year>2013</year>
          <volume>31</volume>
          <fpage>1837</fpage>
          <lpage>1846</lpage>
          <pub-id pub-id-type="doi">10.1097/HJH.0b013e3283622198</pub-id>
          <pub-id pub-id-type="pmid">23751965</pub-id>
        </element-citation>
      </ref>
      <ref id="CR37">
        <label>37.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kristal-Boneh</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Froom</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Harari</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Shapiro</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Green</surname>
              <given-names>MS</given-names>
            </name>
          </person-group>
          <article-title>Seasonal changes in red blood cell parameters</article-title>
          <source>Br J Haematol</source>
          <year>1993</year>
          <volume>85</volume>
          <fpage>603</fpage>
          <lpage>607</lpage>
          <pub-id pub-id-type="doi">10.1111/j.1365-2141.1993.tb03354.x</pub-id>
          <pub-id pub-id-type="pmid">8136283</pub-id>
        </element-citation>
      </ref>
      <ref id="CR38">
        <label>38.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Cal&#xF2;</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Davis</surname>
              <given-names>PA</given-names>
            </name>
            <name>
              <surname>Rossi</surname>
              <given-names>GP</given-names>
            </name>
          </person-group>
          <article-title>Understanding the mechanisms of angiotensin II signaling involved in hypertension and its long-term sequelae: insights from Bartter&#x2019;s and Gitelman&#x2019;s syndromes, human models of endogenous angiotensin II signaling antagonism</article-title>
          <source>J Hypert</source>
          <year>2014</year>
          <volume>32</volume>
          <fpage>2109</fpage>
          <lpage>2119</lpage>
          <pub-id pub-id-type="doi">10.1097/HJH.0000000000000321</pub-id>
        </element-citation>
      </ref>
      <ref id="CR39">
        <label>39.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Maiolino</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Naso</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Cal&#xF2;</surname>
              <given-names>LA</given-names>
            </name>
          </person-group>
          <article-title>Angiotensin II type 2 receptor effects: lesson from a human model of vascular hyporeactivity. Letter regarding Kemp et al.</article-title>
          <source>Circ Res</source>
          <year>2014</year>
          <volume>115</volume>
          <fpage>e24</fpage>
          <lpage>e25</lpage>
          <pub-id pub-id-type="doi">10.1161/CIRCRESAHA.114.304959</pub-id>
          <pub-id pub-id-type="pmid">25301824</pub-id>
        </element-citation>
      </ref>
      <ref id="CR40">
        <label>40.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Rice</surname>
              <given-names>ASC</given-names>
            </name>
            <name>
              <surname>Dworkin</surname>
              <given-names>RH</given-names>
            </name>
            <name>
              <surname>McCarthy</surname>
              <given-names>TD</given-names>
            </name>
            <name>
              <surname>Anand</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Bountra</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>McCloud</surname>
              <given-names>PI</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>EMA401, an orally administered highly selective angiotensin II type 2 receptor antagonist, as a novel treatment for postherpetic neuralgia: a randomised, double-blind, placebo-controlled phase 2 clinical trial</article-title>
          <source>Lancet</source>
          <year>2014</year>
          <volume>383</volume>
          <fpage>1637</fpage>
          <lpage>1647</lpage>
          <pub-id pub-id-type="doi">10.1016/S0140-6736(13)62337-5</pub-id>
          <pub-id pub-id-type="pmid">24507377</pub-id>
        </element-citation>
      </ref>
      <ref id="CR41">
        <label>41.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>James</surname>
              <given-names>PA</given-names>
            </name>
            <name>
              <surname>Oparil</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Carter</surname>
              <given-names>BL</given-names>
            </name>
            <name>
              <surname>Cushman</surname>
              <given-names>WC</given-names>
            </name>
            <name>
              <surname>Dennison-Himmelfarb</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Handler</surname>
              <given-names>J</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8)</article-title>
          <source>JAMA</source>
          <year>2014</year>
          <volume>311</volume>
          <fpage>507</fpage>
          <lpage>520</lpage>
          <pub-id pub-id-type="doi">10.1001/jama.2013.284427</pub-id>
          <pub-id pub-id-type="pmid">24352797</pub-id>
        </element-citation>
      </ref>
      <ref id="CR42">
        <label>42.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Paratia</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Bilo</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
          <article-title>Evening administration of antihypertensive drugs: filling a knowledge gap</article-title>
          <source>J Hypertens</source>
          <year>2010</year>
          <volume>28</volume>
          <fpage>1390</fpage>
          <lpage>1392</lpage>
          <pub-id pub-id-type="doi">10.1097/HJH.0b013e32833c131d</pub-id>
          <pub-id pub-id-type="pmid">20574250</pub-id>
        </element-citation>
      </ref>
      <ref id="CR43">
        <label>43.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Fuchs</surname>
              <given-names>FD</given-names>
            </name>
            <name>
              <surname>Fuchs</surname>
              <given-names>SC</given-names>
            </name>
          </person-group>
          <article-title>Blood pressure targets in the treatment of high blood pressure: a reappraisal of the J-shaped phenomenon</article-title>
          <source>J Hum Hypertens</source>
          <year>2014</year>
          <volume>28</volume>
          <fpage>80</fpage>
          <lpage>84</lpage>
          <pub-id pub-id-type="doi">10.1038/jhh.2013.78</pub-id>
          <pub-id pub-id-type="pmid">23966174</pub-id>
        </element-citation>
      </ref>
      <ref id="CR44">
        <label>44.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Konstam</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Neaton</surname>
              <given-names>JD</given-names>
            </name>
            <name>
              <surname>Dickstein</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Drexler</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Komajda</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Martinez</surname>
              <given-names>FA</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial</article-title>
          <source>Lancet</source>
          <year>2009</year>
          <volume>374</volume>
          <fpage>1840</fpage>
          <lpage>1848</lpage>
          <pub-id pub-id-type="doi">10.1016/S0140-6736(09)61913-9</pub-id>
          <pub-id pub-id-type="pmid">19922995</pub-id>
        </element-citation>
      </ref>
      <ref id="CR45">
        <label>45.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gasparrini</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Guo</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Hashizume</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Lavigne</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Zanobetti</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Schwartz</surname>
              <given-names>J</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Mortality risk attributable to high and low ambient temperature: a multicountry observational study</article-title>
          <source>Lancet</source>
          <year>2015</year>
          <pub-id pub-id-type="pmid">26003380</pub-id>
        </element-citation>
      </ref>
      <ref id="CR46">
        <label>46.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Elgendy</surname>
              <given-names>IY</given-names>
            </name>
            <name>
              <surname>Huo</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Chik</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Pepine</surname>
              <given-names>CJ</given-names>
            </name>
            <name>
              <surname>Bavry</surname>
              <given-names>AA</given-names>
            </name>
          </person-group>
          <article-title>Efficacy and safety of angiotensin receptor blockers in older patients: a meta-analysis of randomized trials</article-title>
          <source>Am J Hypert</source>
          <year>2015</year>
          <volume>28</volume>
          <fpage>576</fpage>
          <lpage>585</lpage>
          <pub-id pub-id-type="doi">10.1093/ajh/hpu209</pub-id>
        </element-citation>
      </ref>
      <ref id="CR47">
        <label>47.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Palmer</surname>
              <given-names>SC</given-names>
            </name>
            <name>
              <surname>Mavridis</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Navarese</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Craig</surname>
              <given-names>JC</given-names>
            </name>
            <name>
              <surname>Tonelli</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Salanti</surname>
              <given-names>G</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Comparative efficiency and safety of blood pressure-lowering agents in adults with diabetes and kidney disease: a network meta-analysis</article-title>
          <source>Lancet</source>
          <year>2015</year>
          <volume>385</volume>
          <fpage>2047</fpage>
          <lpage>2056</lpage>
          <pub-id pub-id-type="doi">10.1016/S0140-6736(14)62459-4</pub-id>
          <pub-id pub-id-type="pmid">26009228</pub-id>
        </element-citation>
      </ref>
      <ref id="CR48">
        <label>48.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sanayan</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Westendorp</surname>
              <given-names>RGJ</given-names>
            </name>
          </person-group>
          <article-title>Blood pressure control and cognitive impairment&#x2014;why low is not always better</article-title>
          <source>JAMA Int Med</source>
          <year>2015</year>
          <volume>175</volume>
          <fpage>586</fpage>
          <lpage>587</lpage>
          <pub-id pub-id-type="doi">10.1001/jamainternmed.2014.8202</pub-id>
        </element-citation>
      </ref>
      <ref id="CR49">
        <label>49.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Verberk</surname>
              <given-names>WJ</given-names>
            </name>
            <name>
              <surname>Kroon</surname>
              <given-names>AA</given-names>
            </name>
            <name>
              <surname>Lenders</surname>
              <given-names>JWM</given-names>
            </name>
            <name>
              <surname>Kessels</surname>
              <given-names>AGH</given-names>
            </name>
            <name>
              <surname>van Montfrans</surname>
              <given-names>GA</given-names>
            </name>
            <name>
              <surname>Smit</surname>
              <given-names>AJ</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Self-measurement of blood pressure at home reduces the need for antihypertensive drugs. A randomized, controlled trial</article-title>
          <source>Hypertension</source>
          <year>2007</year>
          <volume>50</volume>
          <fpage>1019</fpage>
          <lpage>1025</lpage>
          <pub-id pub-id-type="doi">10.1161/HYPERTENSIONAHA.107.094193</pub-id>
          <pub-id pub-id-type="pmid">17938383</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
